<DOC>
	<DOCNO>NCT02182479</DOCNO>
	<brief_summary>Study demonstrate least one two dos Berodual® ( 50 µg fenoterol hydrobromide/20 µg ipratropium bromide 25 µg fenoterol hydrobromide/10 µg ipratropium bromide , 1 puff q.i.d . ) administer via Respimat® give bronchodilator response inferior obtain one dose Berodual® ( 50 µg fenoterol hydrobromide/21 µg ipratropium bromide , 2 puff q.i.d . ) administer via MDI safety profile least good asthma patient treat 12 week .</brief_summary>
	<brief_title>Safety Efficacy Berodual® Respimat® Compared Berodual® MDI ( Metered Dose Inhaler ) Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Fenoterol , ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<criteria>Diagnosis bronchial asthma accord ATS ( American Thoracic Society ) Age : 18 65 year Screening FEV1 : 40 80 % predict normal . Predicted normal value base guideline standardise function test European Community Coal Steel Airway obstruction reversibility : increase FEV1 12 % baseline ≥ 200 ml baseline 30 minute 2 puff Berodual® MDI Current nonsmoker exsmoker ( smoke history ≤ 10 packyears ) cessation smoke ≥ 1 year prior screen visit Male female patient Ability train proper use MDI RESPIMAT® device Ability perform technically satisfactory pulmonary function test No hospital admission exacerbation stable dosage pulmonary medication last four week ( except long act β2 agonist ) Willingness ability sign inform consent form prior participation trial Patients significant disease asthma , e.g . history clinically significant cardiovascular , renal , neurological , hepatic endocrine dysfunction . A clinically significant disease define disease opinion investigator may either put patient risk participation study may influence result study ability patient participate complete study History myocardial infarction within last year Tuberculosis indication treatment History cancer within last five year , exclude treat basal cell carcinoma Patients undergone thoracotomy pulmonary resection one bulla , subsequent impair thoracic muscle performance lead unsatisfactory lung function test Current psychiatric disorder History life threaten pulmonary obstruction , cystic fibrosis bronchiectasis An upper low respiratory tract infection four week prior screen visit ( = Visit 1 ) 2week runin period Patients clinically significant abnormal baseline haematology , blood chemistry urinalysis , abnormality defines disease list exclusion criterion Patients AST/ALT ( aspartate amino transferase/alanine amino transferase ) ( SGOT/SGPT ( serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase ) ) &gt; 200 % , bilirubin &gt; 150 % ( except isolate bilirubin increase due Gilbert 's Syndrome ) , creatinine &gt; 125 % upper limit normal range Intolerance aerosolise fenoterol ipratropiumcontaining product , and/or hypersensitivity MDI ingredients Patients use oral corticosteroid medication unstable ( i.e . le 4 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day Betablocker medication Patients take investigational drug one month six halflives ( whichever great ) prior screen visit History drug abuse and/or alcoholism Pregnant nursing woman woman childbearing potential less 2 year postmenopausal , use medically approve mean contraception ( oral contraceptive , intrauterine device surgical Sterilisation ) Previous participation study Patients need 8 puff salbutamol ( 100 µg per puff ) rescue medication 3 consecutive day runin period Severe bronchial asthma frequent nocturnal asthma attack acute exacerbation induce recurrent bronchial infection several time per year Patients know hypersensitivity anticholinergic drug Patients know symptomatic prostatic hypertrophy bladder neck obstruction Patients know narrowangle glaucoma Patients fill least 80 % diary runin period , medication take peak expiratory flow rate ( PEFR ) measurement consider compliant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>